Avacta Group PLC Appointment of a Senior Executive
September 22 2014 - 2:01AM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
22 September 2014
Avacta Group plc
("Avacta" or the "Group")
Appointment of a Senior Business Development Executive
Avacta Group plc (AIM: AVCT), the global provider of proprietary
diagnostic tools, consumables and reagents for human and animal
healthcare, announces that Dr Daniel Gare has joined Avacta Life
Sciences' business development team effective as of 21(st)
September. Dr Gare joins Avacta from Abcam plc ("Abcam") where he
was Head of Strategic Accounts Europe with commercial
responsibility for custom products across Europe.
Dr Gare is an experienced business development specialist with a
proven track record in driving sales and developing new
opportunities in the pharmaceutical, biotech and academic sectors.
His role at Abcam was focused on identifying and evaluating
licencing opportunities to drive revenue and expand brand presence
and awareness and on the commercialisation of bespoke, bulk and
custom products including Epitomics' RabMabs. Dr Gare has
significant experience and knowledge relevant to the
commercialisation of Affimers, Avacta's engineered alternative to
antibodies.
Prior to his period of employment at Abcam, Dr Gare held key
roles in Roche Diagnostics UK where he undertook the responsibility
for sales of the Translational Diagnostics (TDx) product line in
the UK, Ireland and the Nordic countries. Daniel holds a BSc (Hons)
degree in biology from Imperial College, London and a PhD from the
University of Aberdeen.
Commenting on the appointment, Alastair Smith, CEO of Avacta
said: "I am absolutely delighted that Dan is joining the business
development team at Avacta Life Sciences to commercialise Affimers.
He has a proven track record in the sector and, after a number of
years at Abcam, brings a wealth of experience and knowledge about
the market demand for affinity reagents as well as an excellent
commercial network. This is an important appointment for the Group
and the fact that we are attracting such high calibre individuals
is a further validation of the commercial opportunity for
Affimers."
Enquiries:
Avacta Group plc Tel: +44 (0) 844 414
Alastair Smith, Chief Executive Officer 0452
Tim Sykes, Chief Financial Officer www.avacta.com
Numis Securities Limited Tel: +44 (0) 207 260
Michael Meade / Freddie Barnfield - Nominated 1000
Adviser www.numiscorp.com
James Black - Corporate Broking
Media Enquiries Tel: +44 (0) 207 933
Walbrook PR Ltd 8780
Anna Dunphy / Mike Wort avacta@walbrookpr.com
About Avacta Group plc - www.avacta.com
Avacta Group plc is a global provider of innovative
technologies, consumables and reagents for the life science
markets, from drug discovery to diagnostics. Avacta operates
through three divisions:
Avacta Analytical High throughput analysis instrument, Optim,
www.avactaanalytical.com to help reduce the cost and risk of drug development.
--------------------------------------- -------------------------------------------------------
Avacta Animal Health Veterinary diagnostics reference laboratory,
www.avactaanimalhealth.com diagnostic kits and newly launched in-clinic
blood analyser, Sensipod.
--------------------------------------- -------------------------------------------------------
Avacta Life Sciences Novel non-antibody affinity reagents called
www.avactalifesciences.com Affimers, with a wide range of Life Science
applications in diagnostics, drug and biomarker
discover and biotech research and development.
--------------------------------------- -------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAKNNFDELEFF
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024
